Search research articles
Contact Us
Filters
Showing results (61-70 of 92) with videos related to
Page
of 10
Sort By:
Breast Cancer Research and Treatment
|
March 23, 2010
Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer
E A Reijm, M P H M Jansen, K Ruigrok-Ritstier, et al.
Breast Cancer Research and Treatment
|
November 19, 2011
High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer
M P H M Jansen, E A Reijm, A M Sieuwerts, et al.
British Journal of Cancer
|
November 12, 2009
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer
T van Agthoven, A M Sieuwerts, J Veldscholte, et al.
Acta Oncologica (Stockholm, Sweden)
|
November 15, 2016
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis
A Kollár, R L Jones, S Stacchiotti, et al.
Gynecologic Oncology
|
March 26, 2016
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072
C Benson, I Ray-Coquard, S Sleijfer, et al.
The British Journal of Surgery
|
November 21, 2019
Radiomics approach to distinguish between well differentiated liposarcomas and lipomas on MRI
M Vos, M P A Starmans, M J M Timbergen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 7, 2014
High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer
E A Reijm, A M Timmermans, M P Look, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Molecular Tumor Boards: current practice and future needs
D L van der Velden, C M L van Herpen, H W M van Laarhoven, et al.
Scientific Reports
|
February 4, 2018
Sensitive detection of mitochondrial DNA variants for analysis of mitochondrial DNA-enriched extracts from frozen tumor tissue
M J A Weerts, E C Timmermans, R H A M Vossen, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
April 3, 2008
[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus]
P H M de Mulder, J B A G Haanen, S Sleijfer, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 92) with videos related to
Sort By:
Page
of 10
Breast Cancer Research and Treatment
|
March 23, 2010
Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer
E A Reijm, M P H M Jansen, K Ruigrok-Ritstier, et al.
Breast Cancer Research and Treatment
|
November 19, 2011
High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer
M P H M Jansen, E A Reijm, A M Sieuwerts, et al.
British Journal of Cancer
|
November 12, 2009
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer
T van Agthoven, A M Sieuwerts, J Veldscholte, et al.
Acta Oncologica (Stockholm, Sweden)
|
November 15, 2016
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis
A Kollár, R L Jones, S Stacchiotti, et al.
Gynecologic Oncology
|
March 26, 2016
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072
C Benson, I Ray-Coquard, S Sleijfer, et al.
The British Journal of Surgery
|
November 21, 2019
Radiomics approach to distinguish between well differentiated liposarcomas and lipomas on MRI
M Vos, M P A Starmans, M J M Timbergen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 7, 2014
High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer
E A Reijm, A M Timmermans, M P Look, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Molecular Tumor Boards: current practice and future needs
D L van der Velden, C M L van Herpen, H W M van Laarhoven, et al.
Scientific Reports
|
February 4, 2018
Sensitive detection of mitochondrial DNA variants for analysis of mitochondrial DNA-enriched extracts from frozen tumor tissue
M J A Weerts, E C Timmermans, R H A M Vossen, et al.
Nederlands Tijdschrift Voor Geneeskunde
|
April 3, 2008
[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus]
P H M de Mulder, J B A G Haanen, S Sleijfer, et al.
Page
of 10